CAR-NK cells are allogeneic effector cells that can be easily expanded and modified, which can enhance the universality and simplicity of treatment, and make up for the weakness of autoimmune cells in patients with advanced cancer. CAR-NK cells kill target cells through CAR-dependent and NK cell receptor-dependent mechanisms that have eliminated tumor cells positive for tumor-associated antigens or tumor cells expressing NK cell receptor ligands. Shenzhen Cell Valley will provide the whole process service from NK cell collection, transduction to amplification, and the efficiency of transduction of foreign genes can reach more than 50%, which can help customers accelerate the research process in the field of CAR-NK.
CAR-NK cells are allogeneic effector cells that can be easily expanded and modified, which can enhance the universality and simplicity of treatment, and make up for the weakness of autoimmune cells in patients with advanced cancer. Cell Valley provides R&D and outsourcing production services for CAR-NK cells with different targets.
Shenzhen Cell Valley Biopharmaceutical Co., Ltd. is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.